Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.52 |
| ▸ | ARG2 | P78540 | 2/20 | 0.52 |
| ▸ | GGT1 | P19440 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601002 | 1.00 | ARG1 (0.52) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL600647 | 1.00 | ARG1 (0.52) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL599813 | 0.94 | ARG1 (0.55) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL599814 | 0.94 | ARG1 (0.55) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL601232 | 0.94 | ARG1 (0.55) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL600736 | 0.92 | ARG1 (0.53) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL602186 | 0.92 | ARG1 (0.53) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL600737 | 0.92 | ARG1 (0.53) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL600192 | 0.88 | GGT1 (0.50) | ARG1ARG2GGT1CYP1A2CYP2D6 | |
| SCHEMBL602005 | 0.88 | GGT1 (0.50) | ARG1ARG2GGT1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042961-A1 | P53 PEPTIDOMIMETIC MACROCYCLES | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) | 2025-02-06 | — | — | US | claimed |
| US-20250034211-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | MERCK SHARP & DOHME LLC (US) | 2025-01-30 | — | — | US | claimed |
| EP-4444740-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | Merck Sharp & Dohme LLC (US) | 2024-10-16 | — | — | EP | claimed |
| EP-4441067-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | Merck Sharp & Dohme LLC (US) | 2024-10-09 | — | — | EP | claimed |
| WO-2023107353-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | MERCK SHARP & DOHME LLC (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023096947-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | MERCK SHARP & DOHME LLC (US) | 2023-06-01 | — | — | WO | claimed |
| EP-2564863-B1 | Triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2017-08-23 | — | — | EP | claimed |
| EP-2564862-B1 | Substituted amino acids for preparing triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2017-08-02 | — | — | EP | claimed |
| CN-101663044-B | Triazole macrocycle systems | AILERON THERAPEUTICS INC | 2014-07-23 | — | — | CN | claimed |
| US-8637686-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2014-01-28 | — | — | US | claimed |
| EP-2564863-A2 | Triazole linked macrocyclic peptides | Aileron Therapeutics, Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2564862-A2 | Triazole linked macrocyclic peptides | Aileron Therapeutics, Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2114428-B1 | Triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | claimed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | claimed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | claimed |
| CN-101663044-A | triazole macrocycle systems | AILERON THERAPEUTICS INC | 2010-03-03 | — | — | CN | claimed |
| EP-2114428-A2 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | claimed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | claimed |
| US-20250042961-A1 | P53 PEPTIDOMIMETIC MACROCYCLES | AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) | 2025-02-06 | — | — | US | disclosed |
| US-20250034211-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | MERCK SHARP & DOHME LLC (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4444740-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | Merck Sharp & Dohme LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4441067-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | Merck Sharp & Dohme LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023107353-A2 | P53 PEPTIDOMIMETIC MACROCYCLES | MERCK SHARP & DOHME LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023096947-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | MERCK SHARP & DOHME LLC (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190225650-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10308699-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10300109-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| CN-109627287-A | Triazole macrocycle systems | 爱勒让治疗公司 | 2019-04-16 | — | — | CN | disclosed |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | AILERON THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190071469-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2019-03-07 | — | — | US | disclosed |
| CN-109414470-A | Companion diagnostic tools for peptidomimetic macrocycles | 艾瑞朗医疗公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3432904-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180371044-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| CN-108929375-A | Peptidomimetic macrocyclic compound | 爱勒让治疗公司 | 2018-12-04 | — | — | CN | disclosed |
| CN-108912211-A | Triazole crosslinking and thioether crosslinking peptidomimetic macrocyclic compound | 爱勒让治疗公司 | 2018-11-30 | — | — | CN | disclosed |
| US-20180339014-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
| US-20180340009-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
| US-20180273587-A1 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS INC (US) | 2018-09-27 | — | — | US | disclosed |
| WO-2018165575-A2 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-09-13 | — | — | WO | disclosed |
| US-10059741-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| CN-108368161-A | Peptidomimetic macrocycles as MC L-1 modulators | 艾瑞朗医疗公司 | 2018-08-03 | — | — | CN | disclosed |
| US-10030049-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-3347372-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | Aileron Therapeutics, Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022422-B2 | Peptidomimetic macrocycles | Alleron Therapeutics, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9957296-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3301108-A1 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180085426-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2018-03-29 | — | — | US | disclosed |
| EP-2342222-B1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| WO-2017205786-A1 | CELL PERMEABLE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| EP-2376100-B1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| WO-2017165299-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| EP-2564863-B1 | Triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170226177-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-08-10 | — | — | US | disclosed |
| EP-2564862-B1 | Substituted amino acids for preparing triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170107252-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. | 2017-04-20 | — | — | US | disclosed |
| WO-2017044633-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170037086-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| WO-2017004548-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-9522947-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9493509-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160304564-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160289274-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9458202-B2 | Peptidomimetic macrocycles with improved properties | AILERON THERAPEUTICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160251399-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160250278-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160137710-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160108089-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160096873-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160068573-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160052970-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160031936-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9175047-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9175045-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015157508-A1 | PEPTIDOMIMETIC MACROCYCLES WITH PTH ACTIVITY | AILERON THERAPEUTICS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| EP-2926827-A2 | Therapeutic Peptidomimetic Macrocycles | Aileron Therapeutics, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| US-9096684-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150183825-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2015-07-02 | — | — | US | disclosed |
| CN-102482336-B | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2015-05-06 | — | — | CN | disclosed |
| US-9023988-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| CN-104474529-A | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2015-04-01 | — | — | CN | disclosed |
| US-8987414-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150038430-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2015-02-05 | — | — | US | disclosed |
| EP-2819688-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| CN-104144695-A | Triazole-and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2014-11-12 | — | — | CN | disclosed |
| US-20140323701-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| CN-104086641-A | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS INC | 2014-10-08 | — | — | CN | disclosed |
| WO-2014138429-A2 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| CN-104039342-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2014-09-10 | — | — | CN | disclosed |
| EP-2768518-A1 | PEPTIDOMIMETIC MACROCYLES | Aileron Therapeutics, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8808694-B2 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| CN-101663044-B | Triazole macrocycle systems | AILERON THERAPEUTICS INC | 2014-07-23 | — | — | CN | disclosed |
| US-20140135255-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8637686-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8524653-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2013123267-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013059525-A1 | PEPTIDOMIMETIC MACROCYLES | AILERON THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20130072439-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-8399405-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2564863-A2 | Triazole linked macrocyclic peptides | Aileron Therapeutics, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2564862-A2 | Triazole linked macrocyclic peptides | Aileron Therapeutics, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130023646-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| CN-102884074-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2013-01-16 | — | — | CN | disclosed |
| WO-2012173846-A2 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| EP-2114428-B1 | Triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| CN-102712675-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2012-10-03 | — | — | CN | disclosed |
| CN-102655875-A | Improved peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2012-09-05 | — | — | CN | disclosed |
| EP-2488193-A1 | IMPROVED PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2480565-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120190818-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| CN-102482336-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2012-05-30 | — | — | CN | disclosed |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapetics Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012021874-A1 | PEPTIDOMIMETIC MACROCYCLES WITH THIOETHER LINKERS | AILERON THERAPEUTICS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021875-A1 | PEPTIDOMIMETIC MACROCYCLES WITH TRIAZOLE LINKERS | AILERON THERAPEUTICS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC. (US) | 2012-02-16 | — | — | US | disclosed |
| CN-102256615-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2011-11-23 | — | — | CN | disclosed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2376100-A2 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| CN-102223891-A | Peptidomimetic macrocycles with improved properties | AILERON THERAPEUTICS INC | 2011-10-19 | — | — | CN | disclosed |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | NASH HUW M | 2011-10-13 | — | — | US | disclosed |
| CN-102203245-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS | 2011-09-28 | — | — | CN | disclosed |
| CN-102197046-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2011-09-21 | — | — | CN | disclosed |
| CN-102197048-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2011-09-21 | — | — | CN | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2352507-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | Aileron Therapeutics, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2342222-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2342214-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2334697-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2331567-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2329015-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2011047215-A1 | IMPROVED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2310407-A2 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2011038049-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| EP-2285970-A2 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | Aileron Therapeutics, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| CN-101980718-A | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2011-02-23 | — | — | CN | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2242503-A2 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010083347-A2 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010060112-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010034029-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010034034-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010034031-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010034028-A1 | PEPTIDOMIMETIC MARCROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010034026-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| CN-101663044-A | triazole macrocycle systems | AILERON THERAPEUTICS INC | 2010-03-03 | — | — | CN | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009149214-A2 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | AILERON THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2114428-A2 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009126292-A2 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009099677-A2 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225650-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | HIF1A, HIF1AN, EGLN3 | ARG1 121/4885ARG2 29/4885GGT1 2868/4885 |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, CTNNB1, WNT1 | ARG1 4164/4885ARG2 4582/4885GGT1 2783/4885 |
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | ARG1 108/4885ARG2 219/4885GGT1 3198/4885 |
| US-20180339014-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | ARG1 355/4885ARG2 422/4885GGT1 3065/4885 |
| US-10246491-B2 | Peptidomimetic macrocycles and use thereof in regulating HIF1alpha | HIF1A, HIF1AN, EGLN3 | ARG1 121/4885ARG2 29/4885GGT1 2868/4885 |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | MCL1, BCL2L1, BCL2L11 | ARG1 1139/4885ARG2 524/4885GGT1 1938/4885 |
| US-20160096873-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | ARG1 904/4885ARG2 913/4885GGT1 2285/4885 |
| US-20160289274-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | ARG1 108/4885ARG2 219/4885GGT1 3198/4885 |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | ARG1 204/4885ARG2 121/4885GGT1 2156/4885 |
| US-10308699-B2 | Peptidomimetic macrocycles | GHRHR, GHSR, GHITM | ARG1 331/4885ARG2 520/4885GGT1 1662/4885 |
| US-10030049-B2 | Triazole macrocycle systems | FLT3, VIP, NGLY1 | ARG1 108/4885ARG2 219/4885GGT1 3198/4885 |
| US-20140135255-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | ARG1 904/4885ARG2 913/4885GGT1 2285/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | ARG1 848/4885ARG2 791/4885GGT1 820/4885 |
| US-20180085426-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | ARG1 204/4885ARG2 121/4885GGT1 2156/4885 |
| US-20170226177-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | ARG1 331/4885ARG2 520/4885GGT1 1662/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | ARG1 108/4885ARG2 219/4885GGT1 3198/4885 |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | ARG1 798/4885ARG2 1207/4885GGT1 561/4885 |
| US-20120190818-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | ARG1 108/4885ARG2 219/4885GGT1 3198/4885 |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | ARG1 204/4885ARG2 121/4885GGT1 2156/4885 |
| US-20130023646-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | ARG1 848/4885ARG2 791/4885GGT1 820/4885 |
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | ARG1 2576/4885ARG2 1399/4885GGT1 2088/4885 |
| US-20160251399-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | ARG1 355/4885ARG2 422/4885GGT1 3065/4885 |
| US-20190071469-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | ARG1 197/4885ARG2 474/4885GGT1 2267/4885 |
| US-20150038430-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | ARG1 197/4885ARG2 474/4885GGT1 2267/4885 |
| US-20160031936-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | ARG1 108/4885ARG2 219/4885GGT1 3198/4885 |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | ARG1 331/4885ARG2 520/4885GGT1 1662/4885 |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | BCL2L11, BCL2L1, BCL2L13 | ARG1 4034/4885ARG2 2781/4885GGT1 845/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | ARG1 904/4885ARG2 913/4885GGT1 2285/4885 |
| US-20130072439-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, WNT1, CTNNB1 | ARG1 4252/4885ARG2 4537/4885GGT1 3021/4885 |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | ARG1 355/4885ARG2 422/4885GGT1 3065/4885 |
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | ARG1 128/4885ARG2 199/4885GGT1 2457/4885 |
| US-20160250278-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | ARG1 355/4885ARG2 422/4885GGT1 3065/4885 |
| US-20180371044-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | ARG1 331/4885ARG2 520/4885GGT1 1662/4885 |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | ARG1 687/4885ARG2 519/4885GGT1 2426/4885 |
| US-20160108089-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | ARG1 848/4885ARG2 791/4885GGT1 820/4885 |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | IL33, TPR, CDC37 | ARG1 128/4885ARG2 199/4885GGT1 2457/4885 |
| US-20160137710-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | ARG1 331/4885ARG2 520/4885GGT1 1662/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | ARG1 204/4885ARG2 121/4885GGT1 2156/4885 |
| US-10059741-B2 | Peptidomimetic macrocycles | ZC3HAV1, HAVCR2, ZC3HAV1L | ARG1 355/4885ARG2 422/4885GGT1 3065/4885 |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | SLC29A2, SLC29A1, SLC22A3 | ARG1 1843/4885ARG2 387/4885GGT1 2869/4885 |
| US-20180273587-A1 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | BCL2L11, BCL2L1, BCL2L13 | ARG1 4034/4885ARG2 2781/4885GGT1 845/4885 |
| US-20170298099-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | ARG1 848/4885ARG2 791/4885GGT1 820/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | ARG1 848/4885ARG2 791/4885GGT1 820/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | ARG1 687/4885ARG2 519/4885GGT1 2426/4885 |
| US-20170299576-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | ARG1 904/4885ARG2 913/4885GGT1 2285/4885 |
| US-20250034211-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | TP53, MDM4, MDM2 | ARG1 986/4885ARG2 901/4885GGT1 2192/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | ARG1 197/4885ARG2 474/4885GGT1 2267/4885 |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | ARG1 197/4885ARG2 474/4885GGT1 2267/4885 |
| US-20180340009-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | MCL1, BCL2L1, BCL2L11 | ARG1 1139/4885ARG2 524/4885GGT1 1938/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | ARG1 331/4885ARG2 520/4885GGT1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.